ArticleDisease models & mechanisms2014
A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12.
Article in Disease models & mechanisms, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma.Journal of neuro-oncology · 2025Review
- What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.Cancers · 2022Review
- Personalized chordoma organoids for drug discovery studies.Science advances · 2022Article
- Review
- A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma.Frontiers in oncology · 2022Review
- Genetic Engineering of Zebrafish in Cancer Research.Cancers · 2020Review
- New Prospects for Molecular Targets for Chordomas.Neurosurgery clinics of North America · 2020Review
- [Chordoma: is there a molecular basis for diagnosis and treatment?]Der Pathologe · 2020Review
- Zebrafish: A Resourceful Vertebrate Model to Investigate Skeletal Disorders.Frontiers in endocrinology · 2020Review
- TheAutophagy · 2019Article
- Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.Disease models & mechanisms · 2019Article
- The driver landscape of sporadic chordoma.Nature communications · 2017Article
- Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors.Biomedicines · 2017Review
- Chordoma: an update on the pathophysiology and molecular mechanisms.Current reviews in musculoskeletal medicine · 2015Article
- The notochord: structure and functions.Cellular and molecular life sciences : CMLS · 2015Review
- Primary intestinal and vertebral chordomas in laboratory zebrafish (Danio rerio).Veterinary pathology · 2015Article
- FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation.Oncotarget · 2014Article
- Spotlight on zebrafish: translational impact.Disease models & mechanisms · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Chordoma is a malignant tumor thought to arise from remnants of the embryonic notochord, with its origin in the bones of the axial skeleton. Surgical resection is the standard treatment, usually in combination with radiation therapy, but neither chemotherapeutic nor targeted therapeutic approaches have demonstrated success. No animal model and only few chordoma cell lines are available for preclinical drug testing, and, although no druggable genetic drivers have been identified, activation of EGFR and downstream AKT-PI3K pathways have been described. Here, we report a zebrafish model of chordoma, based on stable transgene-driven expression of HRASV12 in notochord cells during development. Extensive intra-notochordal tumor formation is evident within days of transgene expression, ultimately leading to larval death. The zebrafish tumors share characteristics of human chordoma as demonstrated by immunohistochemistry and electron microscopy. The mTORC1 inhibitor rapamycin, which has some demonstrated activity in a chordoma cell line, delays the onset of tumor formation in our zebrafish model, and improves survival of tumor-bearing fish. Consequently, the HRASV12-driven zebrafish model of chordoma could enable high-throughput screening of potential therapeutic agents for the treatment of this refractory cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.